Skip to main content

Table 1 Baseline characteristics of patients

From: Does subcutaneous administration of recombinant human erythropoietin increase thrombotic events in total hip arthroplasty? A prospective thrombelastography analysis

  rHu-EPO group
(n = 74)
Control group
(n = 78)
P value
Age (years) 66.2 ± 10.9 65.7 ± 9.1 0.773
Female sex 44(59.5%) 40(51.3%) 0.311
Weight (kg) 65.9 ± 7.3 65.5 ± 9.1 0.805
Body mass index (kg/m2) 23.8 ± 3.7 23.7 ± 3.6 0.958
Harris score 44.84 ± 11.87 43.53 ± 10.90 0.479
Comorbidity    
 Hypertension
 Diabetes mellitus
39(52.7%)
3(4.1%)
45(57.7%)
9(11.5%)
0.625
0.132
  1. *P < 0.05